Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media


We offer a weekly Journal Club focusing on "Cancer Immunotherapy" which takes place on Mondays at 9.00 a.m. with more than 30 participants from different departments and research programs of the DKFZ and NCT. The seminar participants are Master and PhD students, postdocs and group leaders. Our aim is to critically review the newest literature in the field of cancer immunotherapy.


Each participant presents a paper approximately every 8 months in a 30 to 40 min Powerpoint presentation. The publication is then discussed by all attendies. Since mid of 2015 more than 160 papers have been presented..

Due to the Corona virus situation, the journal club is presently completely virtually given as video conference with a shared presentation. Discussion is possible. 

If you are interested to join, please contact S. Eichmüller, who is organizing this seminar. Participation can be confirmed for the PhD program.

list of papers presented so far can be found here (pdf-file; updated 2022-01-14).


Most recent papers presented (update 2022-01-14)

  • Salzer et al., 2020 Nature Comm Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function
  • Acharaya et al., 2020 Immunity Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment
  • Yamazaki et al., 2020 Nature Immunol Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
  • Park et al., 2020 Sci Transl Med Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
  • Diskin et al., 2020 Nature Immunol PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
  • Lakins et al., 2020 Clin Cancer Res FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models
  • Baharom et al., 2020 Nature Immunol Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
  • Such et al., 2020 JCI Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy
  • Klemm et al., 2020 Cell Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
  • Cichocki et al., 2020 Sci Transl Med iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy
  • Au et al., 2020 Sci Adv Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
  • Polack et al., 2020 NEJM Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
  • Yu et al., 2020 Nature Med Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
  • Cai et al., 2020 Mol Oncol Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1
  • You et al, 2020 J Immunother cancer Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
  • Wang et al., 2020 PlosOne Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function
  • Mosaheb et al., 2020 Nature Comm Genetically stable poliovirus vectors activate dendritic cells and prime anti-tumor CD8 T cell immunity
  • Krishna et al., 2020 Science Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
  • Samstein et al., 2020 NatureCancer Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
  • Xu et al., 2020 JEM STING agonist promotes CAR T cell trafficking and persistence in breast cancer
  • Wu et al., 2020 Nature Peripheral T cell expansion predicts tumour infiltration and clinical response
  • Yang et al., 2021 Nature Comm Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
  • Solomon et al., 2020 Nature Cancer CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
  • Liu et al., 2020 Cell Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
  • Fu et al., 2021 Can Imm Res DGKA Mediates Resistance to PD-1 Blockade
  • Platten et al., 2021 Nature A vaccine targeting mutant IDH1 in newly diagnosed glioma
  • Shield V et al., 2021 Science Advances Cellular backpacks for macrophage immunotherapy
  • Kaczanowska et al., 2021 Cell Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
  • Hu et al., 2021 Nature Med Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
  • Holland et al., 2020 J Clin Invest Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA
  • Cafri et al., 2020 J Clin Invest mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
  • Chen et al., 2021 Cancer Cell Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer
  • Kottke et al., 2021 Nature Comm Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
  • Wie et al., 2021 Nature Comm Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles
  • Eschweiler et al., 2021 Nature Immunol Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
  • Schneider et al., 2021 Sci Transl Med Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
  • Wang et al., 2020 CII Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
  • Nagarsheth et al., 2021 Nature Med TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
  • Reinhardt et al., 2020 Science An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
  • Hamdan et al., 2021 J ImmunoTher cancer Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
  • Johnson et al., 2021 Cell The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function
  • Oliveira et al, 2021 Nature Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
  • Roy at el., 2021 Nature Comm Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
  • Rath et al., 2020 Science Advances Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4+ T cells
  • Zhao et al., 2021 Science Advances Switchable Immune modulator for tumor-specific activation of anticancer immunity
  • Zhai et al, 2021 Nature Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses
  • Choi et al., 2021 Cell Rep Methods Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
  • Yarmarkovich et al., 2021 Nature Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
  • Guo et al., 2021 Nature Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
  • Zuo et al., 2021 Nature Immunol Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
  • Duong et al., 2021 Immunology Type I interferon activates MHC class I-dressed CD11b+conventional dendritic cells to promote protective anti-tumor CD8+T cell immunity
  • Daher et al., 2021 Blood Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

to top
powered by webEdition CMS